arrow_back Back Filing freshness 10-K FY 2026 SEC EDGAR

Propanc Biopharma, Inc.

PPCB
$1.65 ▼ -0.09 (-4.90%) at close
Healthcare ·Pharmaceutical Preparations ·USPharmaceutical Preparations
19 Visible periods
23 Metrics
Peer-ranked Benchmarks
Price Chart
7
Health
Poor
Bearish
auto_awesome

Analytical Summary

Propanc Biopharma, Inc. faces fundamental challenges with weakness in Return on Common Equity (%). The fundamentals warrant careful consideration of downside risks.

Market Cap $1.9M
Dividend Yield —
Revenue Growth —
Op. Margin —
ROIC -152.8% ↗
FCF / Share $-5.06 ↘
Trailing P/E —
Price / Book 0.6x
FCF Yield —
Debt / Equity —
info Valuation on last close. End-of-day price, Nov 5, 2026.

19-Year Financial Trajectory

Annual
Metric Value Trend Year over Year Percentile
Net Income Profit after all expenses
$-18.86M
↑ +68.0% —
FCF / Share Free cash flow per share
$-5.06
↓ -98.3% —
Long-Term Debt Long-term obligations
$537.92K
↑ +34.7% —
trending_up

Bullish Indicators

  • No bullish signals detected.
warning

Bearish Risks

  • Return on Common Equity (%)Return on Common Equity (%) is in the bottom quartile

Health Breakdown

Returns
2
Financial Health ↓
2
Cash Quality ↓
31

bar_chart Data from SEC EDGAR XBRL filings

Synced 5 days ago 19 years · 65 quarters